talimogene laherparepvec + cisplatin

Talimogene laherparepvec + cisplatin is a combination regimen being evaluated primarily in the context of solid tumors, such as triple-negative breast cancer and head and neck squamous cell carcinoma. Talimogene laherparepvec is an oncolytic immunotherapy derived from herpes simplex virus type 1 (HSV-1), genetically modified to express human GM-CSF and selectively replicate within tumor tissue. Its action causes direct tumor cell lysis and systemic anti-tumor immune activation via GM-CSF-mediated dendritic cell recruitment and tumor antigen presentation. Cisplatin is a small molecule platinum-based chemotherapeutic that crosslinks DNA, inhibiting replication and leading to apoptosis. The combination aims to enhance local tumor response and systemic immunity, potentially improving clinical outcomes over standard therapy alone[1][2][3][4][6].

Other names

talimogene laherparepvec and cisplatinT-VEC and cisplatin